Topic: Regulatory Flexibility

FDA Commissioner Stephen Hahn discusses the scaling of antibody testing as a primary tool for returning the American workforce to their jobs. These tests would identify individuals who have recovered and developed immunity, potentially serving as a "safe" certification for human resources. The FDA is reportedly providing regulatory flexibility to developers to speed up the manufacturing of these diagnostic tools.